Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18\~65 years.~* Pregnancy tests of female patients must be negative. All patients with effective birth control measures during treatment period and 6 months after the cessation of treatment.~* Chronic HCV infection evidence: HCV RNA or anti-HCV positive \>6 months; liver biopsy evidence; vital signs, symptoms, exposure history, and results of laboratory test and iconography examination support diagnosis of chronic hepatitis C.~* HCV RNA≥2000IU/ml.~Exclusion Criteria:~* Pregnant or lactating women.~* Mental disorder or physical disability.~* WBC\<3000/mm3, or ANC \<1500/mm3, or PLT \<90,000/mm3.~* Received interferon treatment within the previous 6 months or shew no response to interferon.~* Co-infection with HIV, HAV, HBV, HEV.~* Evidence of hepatic decompensation.~* Chest X-ray with clinically significant active inflammatory process, history of significant pulmonary disease or any history of interstitial lung disease.~* History of hypothyroidism or current treatment for thyroid disease.~* Diabetes mellitus.~* Uncontrolled significant chronic medical conditions other than chronic hepatitis C or other conditions which in the opinion of the investigator preclude enrollment into the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Ypeginterferon alfa-2b 90mcg per Week, with Ribavirin 1000-1200mg/d
- Group 2 (Type: EXPERIMENTAL): Ypeginterferon alfa-2b 135mcg per Week, with Ribavirin 1000-1200mg/d
- Group 3 (Type: EXPERIMENTAL): Ypeginterferon alfa-2b 180mcg per Week, with Ribavirin 1000-1200mg/d
- Group 4 (Type: ACTIVE_COMPARATOR): Pegasys 180mcg per Week, with Ribavirin 1000-1200mg/d

Based on this trial design, predict the completion outcome and termination type (if applicable).